BOULDER, CO--(Marketwired - August 22, 2013) - MBio Diagnostics, Inc. announced today that it has appointed Robert J. Silverman to the MBio Diagnostics, Inc. Board of Directors.
Mr. Silverman served as the CEO of mtm Laboratories AG, an in-vitro diagnostics company that developed and commercialized a portfolio of products for early detection and diagnosis of cervical cancer. He was instrumental in raising capital and building mtm into a global, fully integrated commercial business. Mr. Silverman successfully negotiated the purchase of mtm by Roche Diagnostics in August 2011 for a total deal value of EUR 190 Million and then facilitated the integration of mtm into Roche.
Prior to leading mtm laboratories, he was the Senior Vice-President of Worldwide Commercial Operations for Viacell, a company focused on developing stem cell therapies and cord blood banking. Before this, he spent 6 years with Cytyc Corporation. During his tenure at Cytyc, he served as the Vice President of Marketing and the Vice President of International, and was integral in launching and establishing the core technology (the ThinPrep Pap Test) into the standard of care for cervical cancer screening. Previous positions include Vice-President of Marketing for Pasteur Merieux Connaught, Director of New Product Development for Abbott Laboratories Pharmaceutical Products Division and Management Consultant with Bain and Company. He earned his Master's degree in Marketing and Finance from Kellogg Graduate School of Management Northwestern University and received his Bachelor of Science degree in Pharmacy from the University of Michigan. He currently works with several companies in a Board and Advisory capacity.
Commenting on the addition of Mr. Silverman to the Board, Christopher Myatt, Founder and CEO, MBio Diagnostics, Inc., offered, "This is a critical juncture for MBio Diagnostics, in which we are commercializing our first human diagnostic product. Bob's expertise in the in-vitro diagnostics space will bring the depth and focus that is needed to ensure the company's growth and development."
MBio Diagnostics, Inc. (www.mbiodx.com) is a privately held diagnostics and life sciences company based in Boulder, CO. MBio Diagnostics is increasing access to quality healthcare by delivering innovative and low cost point-of-care (POC) diagnostics. The MBio System is initially being commercialized to manage treatment of HIV patients from a single drop of blood. The MBio detection system is being developed for a pipeline of applications including multiplex assays and cellular analysis.